Oncology Business Management | Specialty

Gottlieb Addresses Coronavirus, Innovation in Keynote Address

March 8th 2020

The novel coronavirus spreading across the world represents a distinct challenge for all physicians, especially oncologists who commonly treat patients who have compromised immune systems.

Coronavirus Puts Oncology Community Conference Schedule in Flux

March 6th 2020

As coronavirus disease 2019 (COVID-19) continues to spread around the world, several oncology-based organizations are taking precautionary measures to protect physicians and patients alike from infection, including making the decision to postpone, or even cancel, select medical conferences.

Protect Your Oncology Practice Against Cyber Thieves

March 5th 2020

While cybersecurity upgrades may require additional software and hardware and come at an expense, experts said the expenses are worth it, as they help avoid government fines for data breaches, data recovery costs, and the potential for loss of public trust.

What Oncologists Need to Know About USP and the Recent Clarification

February 28th 2020

Patients with cancer across the country rely on community oncology practices to provide them with high-quality, coordinated cancer care.

Coronavirus and Cancer: What Oncologists Need to Know

February 27th 2020

Infectious diseases are the second-leading cause of mortality in patients with cancer, whose immune systems are often compromised, so it is essential for providers to keep abreast of the latest developments in the management of coronavirus disease 2019.

Can Pragmatic Trials Bend the Antineoplastic Therapy Cost Curve?

February 26th 2020

Clinical trials in oncology serve several purposes; these efforts ultimately help define and, potentially, modify the "standard of care" in routine cancer management.

Future Directions for Later-Line Therapy in R/R mCRC

February 25th 2020

Role of Immunotherapy in Microsatellite-Stable R/R mCRC

February 25th 2020

Relapsed/Refractory mCRC: Immunotherapy in MSI-High Tumors

February 25th 2020

Management of R/R mCRC: Sequencing for Later-Line Therapies

February 25th 2020

R/R Metastatic CRC: CORRECT, IMblaze370, and ReDOS Trials

February 25th 2020

Third-line and Later-line Therapies in R/R mCRC

February 25th 2020

Role of Rebiopsy and ctDNA Testing at Progression of mCRC

February 25th 2020

Molecular Status and Subsequent Therapies in mCRC

February 25th 2020

Initial Systemic Therapy for Metastatic Colorectal Cancer

February 25th 2020

Continuum of Care in Metastatic Colorectal Cancer

February 25th 2020

ASCO Identifies Additional Ways to Improve Hazardous Drug Safety

February 24th 2020

The United States Pharmacopeial Convention (USP) General Chapter is a good start for improving the protection of healthcare workers exposed to hazardous drugs, but more studies and safety protocols are needed, according to an American Society of Clinical Oncology (ASCO) expert panel that evaluated USP and various other guidelines in a report last year.

Value-Based Care With Two-Sided Risk a Preference in Upcoming Oncology Care Model

February 13th 2020

Oncology practices that are participating in the Centers for Medicare & Medicaid Innovation’s Oncology Care Model are willing to take on two-sided risk with value-based care and shift from a fee-for-service approach.

Oncology Payment Models Fall Short of Desired Goals

February 5th 2020

There is a year and a half remaining in the life of the Oncology Care Model, and although the Centers for Medicare & Medicaid Services has leapt forward with a vision for the next-generation model of care Oncology Care First, many stakeholders feel that the Oncology Care Model is more than enough to think about right now.

FDA Approval in HER2+ Breast Cancer, Priority Review in NSCLC, and More

February 1st 2020